Shulman, David S. http://orcid.org/0000-0002-5994-2604
Chen, Sonja
Hall, David
Nag, Anwesha
Thorner, Aaron R.
Lessnick, Stephen L. http://orcid.org/0000-0001-9645-4434
Stegmaier, Kimberly
Janeway, Katherine A.
DuBois, Steven G.
Krailo, Mark D.
Barkauskas, Donald A.
Church, Alanna J.
Crompton, Brian D. http://orcid.org/0000-0001-9404-6621
Article History
Received: 21 June 2022
Revised: 24 August 2022
Accepted: 30 August 2022
First Online: 11 October 2022
Competing interests
: DSS has received fees for consulting from Boehringer Ingelheim. KAJ has received fees for consulting, travel support or honoraria for speaking from Bayer, Roche, Foundation Medicine and Ipsen. SGD has received fees for consulting and advisory board roles from Amgen, Bayer and Jazz Pharmaceuticals and has received travel expenses from Loxo Oncology, Roche, and Salarius. KS receives grant funding as part of the DFCI/Novartis Drug Discovery Program and from Kronos Bio, is a SAB member with stock options with Auron Therapeutics, and has previously consulted for AstraZeneca. AJC has received consulting fees from Bayer. BDC has received funding for unrelated experiments from Gradalis, and his spouse was previously employed and received equity from Acceleron Pharma.
: Informed consent for the initial collection of samples was obtained at the time each patient enrolled to the approved COG clinical trial or banking study. The need for additional informed consent for the use of banked samples was waived by the Dana-Farber Cancer Institute Institutional Review Board.
: Not applicable.